AMAL Therapeutics

AMAL Therapeutics is a private, clinical-stage biotechnology company pioneering a novel class of therapeutic vaccines. Its proprietary KISIMA® platform combines multiple functional units into a single recombinant protein to generate a powerful, targeted immune activation against cancer cells and pathogens. The company's lead asset, ATP128, is a neoantigen-based therapeutic cancer vaccine that has entered clinical development. AMAL aims to address significant unmet medical needs in oncology by harnessing the immune system to treat established diseases, moving beyond traditional prophylactic vaccines.

KISIMA® platform: a modular recombinant protein vaccine technology integrating a Targeting Unit (antigen), a Danger Unit (adjuvant), and a Transport Unit to induce potent and specific T-cell immunity.

AMAL competes in the crowded therapeutic cancer vaccine arena against companies using mRNA (e.g., BioNTech, Moderna), peptide-based, viral vector, and cell-based platforms. Its differentiation lies in the proprietary protein-based KISIMA design aimed at generating a coordinated, potent T-cell response. Key competitors include Gritstone bio, CureVac, and numerous large pharma oncology divisions.